Retinitis pigmentosa is a rare and hereditary neurodegenerative disease which causes vision loss due to the death of photoreceptors in the retina, and for which there is currently no treatment. A research group headed by professor María Miranda Sanz had previously studied the efficiency of progesterone to ameliorate the death of photoreceptor cells in the retina caused by this disease. Now, in a new project published in the scientific journal Frontiers in Pharmacology, they have observed a higher protective effect of progesterone when combined with a strong antioxidant: lipoic acid.
Dr. María Miranda, professor at the CEU UCH and main researcher of the group, says, “In this new study we verified that both progesterone and the lipoic acid are separately able to protect photoreceptors in the retina from cell death, but their simultaneous application provides even better results than individually. These results, obtained in animal models, administering both substances orally, could be the basis for developing future treatments to ameliorate the eyesight deterioration caused by retinitis pigmentosa. There is currently no treatment for the disease, which represents half of those diseases that degenerate the retina around the world.”
Antioxidant and anti-inflammatory mechanism
Even though the cause of retinitis pigmentosa is genetic, the evolution of the disease and the resulting eyesight loss may be related to oxidative stress factors and inflammation. These factors can be ameliorated on one hand by the hormone progesterone, which has shown its neuroprotective efficiency in several studies, including the one previously carried out by doctor Miranda and her team also on retinosis.
Source: Read Full Article